Navicixizumab

Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer[1][2][3].

Product Specifications

CAS Number

[1638338-43-8]

Product Name Alternative

OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab)

UNSPSC

12352203

Target

Notch

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/navicixizumab.html

Purity

99.83

Solubility

10 mM in DMSO

Smiles

[Navicixizumab]

Molecular Weight

(145.83 kDa)

References & Citations

[1]Fu S, et al. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 Aug 10;40 (23) :2568-2577. |[2]Perez-Fidalgo JA, et al. NOTCH signalling in ovarian cancer angiogenesis. Ann Transl Med. 2020 Dec;8 (24) :1705. |[3]Wan-Ching Yen, et al. Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency. Mol Cancer Ther (2015) 14 (12_Supplement_2) : C164.